<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01919723</url>
  </required_header>
  <id_info>
    <org_study_id>ISSBRIL0077</org_study_id>
    <nct_id>NCT01919723</nct_id>
  </id_info>
  <brief_title>Ticagrelor and Eptifibatide Bolus-Only Versus Ticagrelor and Eptifibatide Bolus Plus Abbreviated Infusion</brief_title>
  <official_title>Pharmacodynamic Effects of Ticagrelor and Eptifibatide Bolus-Only Versus Ticagrelor and Eptifibatide Bolus Plus Abbreviated Infusion in Patients Undergoing Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This purpose of this study is to measure platelet response to ticagrelor and eptifibatide
      bolus-only compared with ticagrelor and eptifibatide bolus plus 2-hour infusion administrated
      after cardiac catheterization in patients undergoing non-emergent percutaneous coronary
      intervention.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, 70 patients with Acute Coronary Syndrome who are undergoing non-emergent
      percutaneous coronary intervention (PCI) will be randomized to ticagrelor loading dose and
      eptifibatide bolus-only versus ticagrelor loading dose and eptifibatide bolus plus 2 hour
      infusion administrated after cardiac catheterization, but before PCI. Platelet function
      testing will be performed at baseline and follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Percent Inhibition of Platelet Aggregation (%IPA)</measure>
    <time_frame>Baseline and 2 hours</time_frame>
    <description>Change from baseline in %IPA at 2 hours after stimulation with 20µM ADP (µM-micromolar, ADP-Adenosine diphosphate), measured in blood by an aggregometer among patients randomized to ticagrelor and 2 boluses of eptifibatide vs. ticagrelor and 2 boluses plus infusion of eptifibatide.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>High On-treatment Platelet Reactivity (HPR)</measure>
    <time_frame>Comparing baseline and follow-up (2 hours)</time_frame>
    <description>Percentage of participants with HPR. HPR is defined as platelet aggregation &gt;59% in response to 20 µM ADP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding Complications</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>Number of subjects that developed gastrointestinal bleeding after Percutaneous Coronary Intervention (PCI). These subjects were categorized under Bleeding Academic Research Consortium 3b. Type 3b bleeding includes overt bleeding plus a hemoglobin drop of ≥5 g/dL (provided the hemoglobin drop is related to bleeding), cardiac tamponade, bleeding requiring surgical intervention for control (excluding dental/nasal/skin/hemorrhoid), and bleeding requiring intravenous vasoactive drugs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Periprocedural Myocardial Infarction (PMI)</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>Number of subjects that developed PMI. Periprocedural myocardial infarction (PMI) was defined as an increase in troponin I values &gt;5 x 99th percentile the upper limit of normal in patients with normal baseline value on admission, or a rise of troponin I values &gt;20% after PCI if the baseline value was elevated.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Ticagrelor and Eptifibatide bolus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ticagrelor 180 mg i.v. Eptifibatide (2 boluses 180µg/Kg each 10 min apart)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ticagrelor &amp; Eptifibatide bolus+infusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ticagrelor 180 mg i.v. Eptifibatide (2 boluses 180µg/Kg, 10 min apart, followed by 2µg/Kg/min infusion for 2 hours)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>Ticagrelor loading dose</description>
    <arm_group_label>Ticagrelor and Eptifibatide bolus</arm_group_label>
    <arm_group_label>Ticagrelor &amp; Eptifibatide bolus+infusion</arm_group_label>
    <other_name>Brilinta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eptifibatide</intervention_name>
    <description>i.v. infusion</description>
    <arm_group_label>Ticagrelor and Eptifibatide bolus</arm_group_label>
    <arm_group_label>Ticagrelor &amp; Eptifibatide bolus+infusion</arm_group_label>
    <other_name>Integrilin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        For inclusion in the study subjects should fulfill the following criteria:

          -  Provision of informed consent prior to any study specific procedures

          -  Males and females aged 19 years and older

          -  Congruent to the PLATO trial, at least two of the following three criteria have to be
             met:

          -  ST-segment changes on electrocardiography, indicating ischemia; (In
             electrocardiography, the ST segment connects the QRS complex and the T wave and has a
             duration of 0.080 to 0.120 sec (80 to 120 ms).

          -  a positive test of a biomarker, indicating myocardial necrosis; or one of several risk
             factors;

          -  age &gt;60 years

          -  previous myocardial infarction or Coronary-Artery Bypass Grafting [CABG];

          -  coronary artery disease with stenosis of ≥50% in at least two vessels;

          -  previous ischemic stroke, transient ischemic attack, carotid stenosis of at least 50%,
             or cerebral revascularization;

          -  diabetes mellitus;

          -  peripheral arterial disease;

          -  or chronic renal dysfunction, defined as a creatinine clearance of &lt;60 ml per minute
             per 1.73 m2 of body surface area).

          -  patients with symptoms of unstable angina lasting ≥10 min and either an elevated
             troponin I level or newly developed ST-segment depression of 1 mm or transient
             ST-segment elevation of 1 mm will also be included.

        Exclusion Criteria:

        Subjects should not enter the study if any of the following exclusion criteria are
        fulfilled:

          -  Patients with active pathological bleeding or a history of intracranial bleeding;

          -  patients with planned to urgent coronary artery bypass graft surgery;

          -  severe hepatic impairment;

          -  concomitant therapy with a strong cytochrome P-450 3A inhibitors, where 3A is s
             subfamily of the cytochrome P450 superfamily of genes;

          -  surgery&lt;4 weeks;

          -  the use of any thienopyridine (within the previous two weeks);

          -  upstream use of Glycoprotein (GP) IIb/IIIa inhibitors;

          -  bleeding diathesis or major bleeding episode within 2 weeks;

          -  a need for oral anticoagulation therapy;

          -  thrombocytopenia;

          -  presence of thrombus in the coronary artery; incessant chest pain or hemodynamic
             instability;

          -  and patients with glomerular filtration rate (GFR)&lt;30 mL/min or on hemodialysis.

          -  maintenance dose of aspirin above 100mg

          -  history of allergies to Ticagrelor

          -  patients at increased risk of bradycardic events (e.g., patients who have sick sinus
             syndrome, 2nd or 3rd degree Atrioventricular block (AV block), or bradycardic related
             syncope and not protected with a pacemaker

          -  women who are pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Massoud Leesar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 3, 2013</study_first_submitted>
  <study_first_submitted_qc>August 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2013</study_first_posted>
  <results_first_submitted>September 27, 2016</results_first_submitted>
  <results_first_submitted_qc>January 9, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">February 28, 2017</results_first_posted>
  <last_update_submitted>January 9, 2017</last_update_submitted>
  <last_update_submitted_qc>January 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Massoud Leesar</investigator_full_name>
    <investigator_title>MD, Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>PCI</keyword>
  <keyword>Ticagrelor</keyword>
  <keyword>Eptifibatide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ticagrelor</mesh_term>
    <mesh_term>Eptifibatide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ticagrelor and Eptifibatide Bolus</title>
          <description>Ticagrelor 180 mg i.v. Eptifibatide (2 boluses 180µg/Kg each 10 min apart)
ticagrelor: ticagrelor loading dose
Eptifibatide: i.v. infusion</description>
        </group>
        <group group_id="P2">
          <title>Ticagrelor &amp; Eptifibatide Bolus+Infusion</title>
          <description>Ticagrelor 180 mg i.v. Eptifibatide (2 boluses 180µg/Kg, 10 min apart, followed by 2µg/Kg/min infusion for 2 hours)
ticagrelor: ticagrelor loading dose
Eptifibatide: i.v. infusion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Blood Samples Hemolyzed</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ticagrelor and Eptifibatide Bolus</title>
          <description>Ticagrelor 180 mg i.v. Eptifibatide (2 boluses 180µg/Kg each 10 min apart)
Ticagrelor: Ticagrelor loading dose
Eptifibatide: i.v. infusion</description>
        </group>
        <group group_id="B2">
          <title>Ticagrelor &amp; Eptifibatide Bolus+Infusion</title>
          <description>Ticagrelor 180 mg i.v. Eptifibatide (2 boluses 180µg/Kg, 10 min apart, followed by 2µg/Kg/min infusion for 2 hours)
Ticagrelor: Ticagrelor loading dose
Eptifibatide: i.v. infusion</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
            <count group_id="B2" value="35"/>
            <count group_id="B3" value="70"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&gt;=19 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Percent Inhibition of Platelet Aggregation (%IPA)</title>
        <description>Change from baseline in %IPA at 2 hours after stimulation with 20µM ADP (µM-micromolar, ADP-Adenosine diphosphate), measured in blood by an aggregometer among patients randomized to ticagrelor and 2 boluses of eptifibatide vs. ticagrelor and 2 boluses plus infusion of eptifibatide.</description>
        <time_frame>Baseline and 2 hours</time_frame>
        <population>2 subjects in each arm did not meet the inclusion criteria (blood hemolyzed) and thus we do not have the primary and secondary outcomes for them.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor and Eptifibatide Bolus</title>
            <description>Ticagrelor 180 mg i.v. Eptifibatide (2 boluses 180µg/Kg each 10 min apart)
ticagrelor: ticagrelor loading dose
Eptifibatide: i.v. infusion</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor &amp; Eptifibatide Bolus+Infusion</title>
            <description>Ticagrelor 180 mg i.v. Eptifibatide (2 boluses 180µg/Kg, 10 min apart, followed by 2µg/Kg/min infusion for 2 hours)
ticagrelor: ticagrelor loading dose
Eptifibatide: i.v. infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percent Inhibition of Platelet Aggregation (%IPA)</title>
          <description>Change from baseline in %IPA at 2 hours after stimulation with 20µM ADP (µM-micromolar, ADP-Adenosine diphosphate), measured in blood by an aggregometer among patients randomized to ticagrelor and 2 boluses of eptifibatide vs. ticagrelor and 2 boluses plus infusion of eptifibatide.</description>
          <population>2 subjects in each arm did not meet the inclusion criteria (blood hemolyzed) and thus we do not have the primary and secondary outcomes for them.</population>
          <units>percentage of IPA</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.59" spread="0.43"/>
                    <measurement group_id="O2" value="99.88" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>High On-treatment Platelet Reactivity (HPR)</title>
        <description>Percentage of participants with HPR. HPR is defined as platelet aggregation &gt;59% in response to 20 µM ADP.</description>
        <time_frame>Comparing baseline and follow-up (2 hours)</time_frame>
        <population>2 subjects in each arm did not meet the inclusion criteria (blood hemolyzed) and thus we do not have the primary and secondary outcomes for them.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor and Eptifibatide Bolus</title>
            <description>Ticagrelor 180 mg i.v. Eptifibatide (2 boluses 180µg/Kg each 10 min apart)
ticagrelor: ticagrelor loading dose
Eptifibatide: i.v. infusion</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor &amp; Eptifibatide Bolus+Infusion</title>
            <description>Ticagrelor 180 mg i.v. Eptifibatide (2 boluses 180µg/Kg, 10 min apart, followed by 2µg/Kg/min infusion for 2 hours)
ticagrelor: ticagrelor loading dose
Eptifibatide: i.v. infusion</description>
          </group>
        </group_list>
        <measure>
          <title>High On-treatment Platelet Reactivity (HPR)</title>
          <description>Percentage of participants with HPR. HPR is defined as platelet aggregation &gt;59% in response to 20 µM ADP.</description>
          <population>2 subjects in each arm did not meet the inclusion criteria (blood hemolyzed) and thus we do not have the primary and secondary outcomes for them.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bleeding Complications</title>
        <description>Number of subjects that developed gastrointestinal bleeding after Percutaneous Coronary Intervention (PCI). These subjects were categorized under Bleeding Academic Research Consortium 3b. Type 3b bleeding includes overt bleeding plus a hemoglobin drop of ≥5 g/dL (provided the hemoglobin drop is related to bleeding), cardiac tamponade, bleeding requiring surgical intervention for control (excluding dental/nasal/skin/hemorrhoid), and bleeding requiring intravenous vasoactive drugs.</description>
        <time_frame>up to 24 hours</time_frame>
        <population>2 subjects in each arm did not meet the inclusion criteria (blood hemolyzed) and thus we do not have the primary and secondary outcomes for them.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor and Eptifibatide Bolus</title>
            <description>Ticagrelor 180 mg i.v. Eptifibatide (2 boluses 180µg/Kg each 10 min apart)
ticagrelor: ticagrelor loading dose
Eptifibatide: i.v. infusion</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor &amp; Eptifibatide Bolus+Infusion</title>
            <description>Ticagrelor 180 mg i.v. Eptifibatide (2 boluses 180µg/Kg, 10 min apart, followed by 2µg/Kg/min infusion for 2 hours)
ticagrelor: ticagrelor loading dose
Eptifibatide: i.v. infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Bleeding Complications</title>
          <description>Number of subjects that developed gastrointestinal bleeding after Percutaneous Coronary Intervention (PCI). These subjects were categorized under Bleeding Academic Research Consortium 3b. Type 3b bleeding includes overt bleeding plus a hemoglobin drop of ≥5 g/dL (provided the hemoglobin drop is related to bleeding), cardiac tamponade, bleeding requiring surgical intervention for control (excluding dental/nasal/skin/hemorrhoid), and bleeding requiring intravenous vasoactive drugs.</description>
          <population>2 subjects in each arm did not meet the inclusion criteria (blood hemolyzed) and thus we do not have the primary and secondary outcomes for them.</population>
          <units>Number of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Periprocedural Myocardial Infarction (PMI)</title>
        <description>Number of subjects that developed PMI. Periprocedural myocardial infarction (PMI) was defined as an increase in troponin I values &gt;5 x 99th percentile the upper limit of normal in patients with normal baseline value on admission, or a rise of troponin I values &gt;20% after PCI if the baseline value was elevated.</description>
        <time_frame>Up to 24 hours</time_frame>
        <population>2 subjects in each arm did not meet the inclusion criteria (blood hemolyzed) and thus we do not have the primary and secondary outcomes for them.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor and Eptifibatide Bolus</title>
            <description>Ticagrelor 180 mg i.v. Eptifibatide (2 boluses 180µg/Kg each 10 min apart)
ticagrelor: ticagrelor loading dose
Eptifibatide: i.v. infusion</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor &amp; Eptifibatide Bolus+Infusion</title>
            <description>Ticagrelor 180 mg i.v. Eptifibatide (2 boluses 180µg/Kg, 10 min apart, followed by 2µg/Kg/min infusion for 2 hours)
ticagrelor: ticagrelor loading dose
Eptifibatide: i.v. infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Periprocedural Myocardial Infarction (PMI)</title>
          <description>Number of subjects that developed PMI. Periprocedural myocardial infarction (PMI) was defined as an increase in troponin I values &gt;5 x 99th percentile the upper limit of normal in patients with normal baseline value on admission, or a rise of troponin I values &gt;20% after PCI if the baseline value was elevated.</description>
          <population>2 subjects in each arm did not meet the inclusion criteria (blood hemolyzed) and thus we do not have the primary and secondary outcomes for them.</population>
          <units>Number of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ticagrelor and Eptifibatide Bolus</title>
          <description>Ticagrelor 180 mg i.v. Eptifibatide (2 boluses 180µg/Kg each 10 min apart)
ticagrelor: ticagrelor loading dose
Eptifibatide: i.v. infusion</description>
        </group>
        <group group_id="E2">
          <title>Ticagrelor &amp; Eptifibatide Bolus+Infusion</title>
          <description>Ticagrelor 180 mg i.v. Eptifibatide (2 boluses 180µg/Kg, 10 min apart, followed by 2µg/Kg/min infusion for 2 hours)
ticagrelor: ticagrelor loading dose
Eptifibatide: i.v. infusion</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Target Lesion Revascularization (TLR)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>NSTEMI</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Periprocedural Myenecrosis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="33"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal Bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mehak Goel ,PhD</name_or_title>
      <organization>University of Alabama at Birmingham</organization>
      <phone>205-975-4021</phone>
      <email>mehakgoel@uabmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

